You are here

Scheduling delegate's final decisions, June 2017

Scheduling medicines and poisons

29 June 2017

Book pagination

4. Summary of delegate's final decisions

Part B - Final decisions on matters not referred to an expert advisory committee

New Chemical Entities – medicines for human therapeutic use

4. Summary of delegate's final decisions

The implementation date of the below final decisions is 1 October 2017 unless separately specified.

Substance Final Decision
Migalastat Schedule 4 – New Entry
MIGALASTAT.
Fosfomycin Schedule 4 – New Entry
FOSFOMYCIN.
Dupilumab Schedule 4 – New Entry
DUPILUMAB.
Influenza virus haemagglutinin Influenza virus haemagglutinin does not require specific scheduling as it is captured by the Schedule 4 group entry for influenza and coryza vaccines.
Bezlotoxumab Schedule 4 – New Entry
BEZLOTOXUMAB.
Rurioctocog alfa pegol Rurioctocog alfa pegol is exempt from scheduling as it falls under Appendix A – General Exemptions under HUMAN BLOOD PRODUCTS.

Book pagination